1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Positive CLL Data For AstraZeneca's BTK Inhibitor Prompts Early ASCEND Trial End

 
• By Sten Stovall

The Calquence Phase III ASCEND trial met its primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukemia and thus will stop early.

Leukemia
Calquence is being developed for the treatment of multiple B-cell blood cancers including CLL. • Source: Shutterstock

AstraZeneca PLC's BTK inhibitor Calquence (acalabrutinib) has boosted its prospects in liquid tumors by meeting the endpoint mid-way in a Phase III trial for relapsed or refractory chronic lymphocytic leukemia (CLL), prompting an early end to the ASCEND evaluation.

Already approved in mantle cell lymphoma (MLL), Calquence is being developed by AstraZeneca and partner Acerta Pharma BV for the treatment of multiple B-cell blood cancers, including diffuse large...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

More from R&D

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.